Photo by nci from unsplash
clinical trial is still ongoing (ClinicalTrials.gov, NCT 2085655). Furthermore, promising response of single agent, chidamide, a new oral HDAC inhibitor, for the treatment of relapsed or refractory NK/ TCL without… Click to show full abstract
clinical trial is still ongoing (ClinicalTrials.gov, NCT 2085655). Furthermore, promising response of single agent, chidamide, a new oral HDAC inhibitor, for the treatment of relapsed or refractory NK/ TCL without significant EBV‐reactivation was recently observed in SYSUCC. PD/PK of chidamide for different dosage and schedule will be presented. Table 1: Comparison of effectiveness between two Groups. EIFRT: Extensive involved field radiotherapy.
Keywords:
molecular characterization;
killer cell;
characterization extranodal;
cell lymphomas;
natural killer;
extranodal natural
Journal Title: Hematological Oncology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Hematological Oncology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!